R heumatoid arthritis (RA) is an autoimmune disease and the most common cause of inflammatory arthritis with a prevalence of 1% to 5%. 1 It is characterized by progressive chronic inflammation resulting in destruction of synovial joints. Patients with RA have a higher overall mortality that is attributed primarily to cardiovascular complications. [1] [2] [3] The underlying pathophysiology leading to increased cardiovascular morbidity and mortality in these patients is not fully understood. However, evidence suggests that a major driving factor is the persistent inflammatory state with high levels of cytokines and inflammatory mediators including C-reactive protein, tumor necrosis factor-α, and interleukins, which damage the endothelium, promote vascular remodeling, and activate the prothrombotic pathways. [3] [4] [5] Perhaps consequently, patients with RA have a higher than normal prevalence of premature atherosclerosis, ischemic heart disease, congestive heart failure, 3 venous thromboembolism, 6 and cardiovascular death. 7, 8 Cardiovascular risk in these patients is further complicated by the chronic use of nonsteroidal anti-inflammatory agents and glucocorticoids. 9 Cardiovascular events are the leading cause of perioperative mortality in patients with RA. Surgery provokes substantial release of inflammatory mediators. The inflammatory response to surgical incision combined with chronic RA-related inflammation may be especially deleterious. However, perioperative cardiovascular complications and mortality in patients with RA have yielded nongeneralized and inconclusive results. 3, [10] [11] [12] Furthermore, American College of Cardiology/American Heart Association guidelines suggest that patients capable of 4 metabolic equivalents have an adequate cardiac function for low-and intermediate-risk surgeries. 13 However, patients with RA may be limited in their functional mobility because of arthritic joints, both decreasing the symptomatic diagnostic utility and increasing the perioperative cardiovascular risk. 2 Thus, we aimed to evaluate cardiac and thromboembolic perioperative complications in patients with RA having noncardiac surgery. Specifically, we tested the primary hypothesis that patients with RA have more postoperative cardiovascular complications than patients without the BACKGROUND: Patients with rheumatoid arthritis have a high overall incidence of mortality, primarily because of cardiovascular complications. Thus, we tested the primary hypothesis that rheumatoid arthritis is independently associated with increased postoperative cardiovascular complications. Second, we determined whether rheumatoid arthritis is associated with increased thromboembolic complications, microcirculatory complications, and mortality. METHODS: We obtained censuses of 2009 to 2010 inpatient hospital discharge data across 7 states (Arizona, California, Florida, Iowa, Maryland, Michigan, and New Jersey). Rheumatoid arthritis was identified using the present-on-admission diagnosis code 714.0. Each rheumatoid arthritis discharge that had surgery was propensity matched to a control discharge. Multivariable logistic regression was used to compare matched rheumatoid arthritis and control patients on risk of in-hospital cardiovascular complications. RESULTS: Among 5.5 million qualifying discharges, the matching procedure yielded successful 66,886 matched pairs. One thousand ninety-five (1.64%) of the matched rheumatoid arthritis discharges and 1006 (1.50%) of the matched controls had in-hospital cardiovascular complications. The adjusted odds ratio (99% confidence interval) was estimated at 1.08 (0.96-1.21; P = 0.08). There were no significant differences in the odds of in-hospital thromboembolic complications (1. We excluded medical visits (as defined by 0 procedures performed) and visits associated with patients younger than 18 years and older than 80 years. We excluded visits corresponding to minor procedures and only kept inpatient visits with surgical procedures.
c RA was identified using the POA diagnosis code 714.0. We considered year of discharge, state of discharge, sex, age, principal procedure code, and all POA diagnosis codes (excluding that specified earlier for RA) as potential confounding variables. Cardiovascular, thromboembolic, and microcirculatory complications were encoded from the diagnosis codes not recorded as POA. In-hospital mortality was available as a binary indicator variable in the discharge record.
Statistical Analysis
To account for potential confounding because of systematic differences among study groups, we matched each RA discharge to a single control discharge. We used a hybrid matching approach to control for potential confounding variables, i.e., exact matching on certain variables and propensity score matching on others. Specifically, we used POA diagnosis codes to estimate the propensity scores for RA and matched each patient with RA to a patient without RA based on the logit of propensity score (within ±0.2 of SDs of the logit propensity score), 14 restricting successful matches to those with common sex, common state of discharge, status on emergency admission, common primary procedure, and difference in age <5 years. The greedy distance-based algorithm was used for the matching. 15 Propensity scores (i.e., the estimated probability of having RA as a function of the patients' other POA diagnoses) were estimated using elastic net logistic regression 16, 17 ; the R statistical software (The R Foundation for Statistical Computing, Vienna, Austria) package "glmnet" was used to fit the propensity model from the aggregated POA diagnosis-related predictors. 18 The elastic net linearly combines the penalties of the lasso and ridge "shrinkage" methods and, therefore, effectively selects among redundant and highly correlated potential predictors and produces estimates with predictive errors lower than the full model.
Primary procedures and diagnosis ICD-9-CM codes are hierarchical and were aggregated for the purpose of the analysis. Each diagnosis code is represented by a maximum of 5 digits, and each procedure code is represented by a maximum of 4 digits. The diagnosis (procedure) codes represented by <10,000 patients were aggregated to a more general diagnosis (or procedure) class. Coupled with an assumed RA incidence of approximately 1%, this implies a minimum cell size of about 100 discharges for any predictor in our propensity model. The diagnosis codes were aggregated up to 4 digits and procedure codes up to 3 digits; aggregated diagnosis (procedure) codes still not meeting the 10,000 patients criterion were removed.
After matching, the balance between RA and normal controls on the aforementioned baseline variables (including all diagnosis-related predictors) was assessed using standard univariable summary statistics (means and SDs, medians and quartiles, or proportions, as appropriate) and standardized difference scores (defined as the difference in means, mean rankings, or proportions divided by a combined estimate of SD). Any baseline variables exhibiting a standardized difference score >0.01 in absolute value was used for adjustment within our final models comparing matched patients on outcomes. 19 For the final models, 4 separate multivariable logistic regressions were used to compare matched patients with RA and controls on risk of in-hospital cardiovascular complications, thromboembolic complications, microcirculatory complications, and mortality (after adjustment for any imbalanced baseline variables according to the definition mentioned earlier). Adjusted odds ratios and 99% confidence intervals (CIs) for each outcome were derived from these models. Respective hypotheses of independent association between RA and each outcome were evaluated using model-based Wald tests with type I error rate (α) conservatively fixed at 0.01.
In a sensitivity analysis, we allowed for the possibility that chronic heart disease might be a mechanism by which RA affects risk of cardiovascular complications (i.e., a mediator rather than a confounder). For this analysis, chronic heart disease was excluded from the estimation of propensity scores. A list of POA ICD-9-CM codes we used to define chronic heart disease is given in Supplemental Appendix 1 (Supplemental Digital Content 1, http://links.lww.com/AA/B274).
RESULTS
Of the 21.50 million discharges included in the statewide censuses, 5.54 million met study inclusion criteria (Fig. 1 set, for an average of 7 per discharge. Overall, 68,489 discharges (1.27%) contained a POA diagnosis code for RA. By sex, this incidence was estimated at 16,965/2.05 million (0.83%) for males and at 51,438/3.45 million (1.49%) for females. Among patients discharged in 2009, the incidence was 33,511/2.80 million (1.20%), whereas in 2010, it was 34,978/2.74 million (1.28%). State-level discharge summaries are given in Table 1 .
Aggregation of the POA diagnosis codes resulted in 678 distinct diagnosis-related covariates (each with >10,000 discharges represented). Among the 37.5 million total POA diagnosis codes, 32.2 million (86%) were successfully mapped. The propensity score model based on these diagnosis-related covariates discriminated between normal and RA discharges moderately well, with a C-statistic (area under the receiver operating characteristic curve) of 0.81. The lasso penalty parameter α of 0.95 was chosen, and the ridge penalty parameter λ of 0.00008 was determined through cross-validation technique. Elastic net logistic regression shrunk 233 (34% of 678 POA diagnosis codes) parameters to 0.
Before matching, 37,255 discharges (0.67%) were removed because of the lack of sex information (86 of which had a POA RA code), and 1132 (0.02%) discharges were removed because of missing data on in-hospital mortality (13 with POA RA code). The matching procedure yielded successful controls for 66,886 of the remaining 68,390 RA discharges (97.8%), and therefore, our final matched sample contained 66,886 matched pairs for a total sample size of n = 133,772. Assessing balance between groups after matching, Table 3 . For the primary outcome, 1095 (1.64%) of the matched RA discharges and 1006 (1.50%) of the matched controls had associated in-hospital cardiovascular complications (Table 3) . Based on the multivariable logistic regression model for this outcome, the adjusted odds ratio (99% CI) was estimated at 1.08 (0.96-1.21), which was not statistically significant (P = 0.08, Wald test; significance criteria of P < 0.01).
For the secondary outcomes (Table 3) , we found no difference in the odds of in-hospital thromboembolic complications (adjusted odds ratio, 1.03; 99% CI, 0.93-1.15; P = 0.42), in the odds of in-hospital microcirculatory complications (adjusted odds ratio, 0.94; 99% CI, 0.86-1.01; P = 0.03), or in-hospital mortality (adjusted odds ratio, 1.11; 99% CI, 0.98-1.25; P = 0.04). Besides, sepsis was diagnosed among 917 (1.37%) patients with RA and 869 (1.30%) control patients.
Excluding chronic heart diseases from the adjustment, results changed from those obtained in our primary analysis. In particular, adjusted odds ratio (99% CI) estimate for cardiovascular complications was 1.11 (0.98-1.25; P = 0.003), that is, a bit higher than estimated in the primary analysis but still not statistically significant. Compared with the primary analysis, approximately 27% of the RA effect size on the cardiovascular complications is explained by the chronic heart diseases supporting that chronic heart disease might be a mediator. For thromboembolic, microcirculatory, and in-hospital mortality, the odds ratios (99% CI) were 1.03 (0.92-1.15; P = 0.50), 0.98 (0.90-1.06; P = 0.49), and 1.01 (0.88-1.15; P = 0.89), respectively.
DISCUSSION
In contrast to our expectations, the incidence of postoperative cardiovascular events, in-hospital thromboembolic complications, and microcirculatory complications in patients with RA was similar to patients without RA. This result is surprising because RA provokes substantial persistent The ASD is equal to the difference in means, mean rankings, or proportions divided by a combined estimate of SD). Any baseline variable exhibiting a standardized difference score >0.01 in absolute value was used for adjustment within our final models comparing matched patients on outcomes.
inflammation that is believed to cause premature development of atherosclerosis, 5 along with venous and arterial thromboembolism. 20 Disability and poor functional status because of arthritis have also been described as risk factors for cardiovascular disease. 21 As expected, the risk of cardiovascular disease is increased by 48% in patients with RA. 22 However, the incidence of postoperative myocardial infarction and other cardiac events in patients with RA was similar to the matched controls in our analysis. Our results are consistent with those of Michaud et al., 10 who also reported no increase in cardiovascular events after total joint arthroplasty in patients with RA. One explanation might be treatments for RA also decrease cardiac risk, including the risk of infarction. 23, 24 For example, blocking tumor necrosis factor-α markedly reduces the risk of infarction. 25 A limitation of our analysis is that we do not know which medications patients are using, much less for how long. Whether pharmacologic treatments for RA moderated 26 or exacerbated 27 perioperative cardiovascular risk thus remains speculative; however, a previous study noted that duration of RA diagnosis had no effect on cardiovascular risk. 28 Inflammation can also increase the risk of both venous and arterial thromboembolism in patients with RA by activating the coagulation system, impairing fibrinolytic pathways, 29 increasing platelet counts, and increasing concentrations of platelet activation markers. 30 For example, Bacani et al. 31 demonstrated a >2-fold increased risk of venous thromboembolic events in a population-based inception cohort of 813 patients with RA, compared with a cohort of non-RA subjects from the same population matched for age and sex with approximately a 10-year follow-up.
As with cardiovascular events, we did not observe increases in thromboembolic or microcirculatory complications, perhaps because most surgical inpatients are given some form of thromboembolic prophylaxis. 32 Furthermore, patients with and without RA were matched for potential confounders, including a history of coronary angioplasty and cardiac bypass, both of which are of vascular origin and mediators of thrombosis. To the extent that thromboembolic events are colinear (i.e., occur in the same patients) with vascular diseases, a true increase in thromboembolic events in patients with RA may have been "adjusted away" in our multivariable analysis.
Another potential factor that may have influenced our results is that our retrospective analysis depended critically on diagnostic billing codes because we matched patients with and without RA for concurrent conditions. RA has no disease-specific diagnostic features, and patients can present with a wide range of manifestations. 33 Consequently, studies suggest that the long lag between symptom onset and the diagnosis of RA is mainly because of late referral rather than patient delay in reporting symptoms or long waits for outpatient appointments. 34 Moreover, in most referral letters from general practitioners, a tentative rheumatologic diagnosis is either unstated or stated wrongly. 35 In-hospital mortality was similar in patients with RA and the control patients. RA, as an autoimmune disease, results in a chronic, systemic inflammatory disorder that may affect many tissues and organs. 36 Contrary to our expectations, there was no difference in mortality maybe because the outcomes are overwhelmingly determined by other baseline and surgical factors.
Some studies show that chronic heart diseases might be associated with RA. 37, 38 Thus, we performed a sensitivity analysis to explore the change in relationship between RA condition and cardiovascular complications in which chronic heart diseases were not used in the model adjustment. After excluding chronic heart diseases from the adjustment, the observed adjusted odds ratio (99% CI) estimate for cardiovascular complications was 1.11 (0.98-1.25; P = 0. 003), which is different from the result of the primary analysis. Based on this finding, the chronic cardiac comorbidities from RA may have been associated with increased postoperative cardiovascular complications, even overall mortality.
By far this is the largest study of RA and perioperative cardiovascular events, with inclusion of 66,886 matched pairs across 7 states broadly representing the US population. We used a unique approach in adjusting for patient's comorbidities, namely deriving aggregated diagnosisrelated predictors based on a minimum cell size criterion and developing a diagnosis-based propensity score for RA, resulting in a comprehensive baseline diagnosis adjustment. We adjusted for confounding variables by strictly matching on procedure, sex, state of discharge, age (to within 5 years), and concurrent diagnoses (through propensity score).
As with all retrospective studies, we cannot be certain that the independent association we found was causal. Although we accounted for thousands of POA diagnoses, age, location, and performed procedure, residual bias because of uncontrolled confounding variables may have remained. Our study is limited by the data elements available in the large data set. For example, race, body mass index, and medication history were among unreported factors that possibly could have impacted the results of this study. Diagnosis codes were dichotomous variables; therefore, we could only adjust for the presence of a disease but not the severity. Another potential limitation of our study is that, in theory, discharges from the states included in our study may not fully represent the general US surgical inpatient population. However, we feel that the risk of such lack of representativeness is low because we have included states that exhibit a spectrum of a geographic locales and socioeconomic characteristics. Another limitation of the study is that the study data set did not contain a unique identifier for a patient; therefore, we were not able to adjust for possibly correlated multiple discharges per patient. We also recognize that excluded rare baseline conditions might be associated with both RA and cardiovascular outcomes and, therefore, might have confounded the results.
In summary, we expected to find an increased risk for cardiovascular, thromboembolic, and microcirculatory complications in patients with RA; our results did not support this association. Furthermore, RA was not independently associated with an increased risk of in-hospital mortality. E
